Post-transplant Lymphoproliferative Disease
📧 Sign up to get email alerts when something new happens for Post-transplant Lymphoproliferative Disease.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2022-10-14First therapy to treat transplant patients with post-transplant lymphoproliferative disease
EMA announces the first therapy approved to treat post-transplant lymphoproliferative disease in transplant patients.
-
CLINICAL_TRIALS trial_result · 2019-09-23Clinical Trial Update: Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma [Phase 2]
Phase 2 trial of chemotherapy for Epstein-Barr Virus-associated lymphomas was terminated; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2018-02-15Clinical Trial Update: Bortezomib Plus Rituximab for EBV+ PTLD [Phase 2]
Phase 2 trial evaluating bortezomib plus rituximab for EBV-positive post-transplant lymphoproliferative disease.
-
CLINICAL_TRIALS trial_result · 2010-03-17Clinical Trial Update: Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD) [Phase 4]
A Phase 4 clinical trial evaluating the combination of fludarabine, cyclophosphamide, doxorubicin, and rituximab for post-transplant lymphop…